Cytokinetics, Incorporated (CYTK)
Company Info
Highlights
$3.84B
-$5.29
-0.42
$19.22M
-$261.27M
-$379.90M
$30.46 - $61.40
$73.45
15.85%
6.43
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Cytokinetics, Incorporated (CYTK) returned -34.93% year-to-date (YTD) and -47.12% over the past 12 months. Over the past 10 years, CYTK delivered an annualized return of 17.84%, outperforming the S&P 500 benchmark at 10.77%.
CYTK
-34.93%
-20.80%
-45.52%
-47.12%
7.62%
17.84%
^GSPC (Benchmark)
0.08%
9.75%
-1.63%
12.74%
15.66%
10.77%
Monthly Returns
The table below presents the monthly returns of CYTK, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 5.14% | -7.00% | -12.63% | 6.59% | -28.55% | -34.93% | |||||||
| 2024 | -6.42% | -7.54% | -2.95% | -12.54% | -20.89% | 11.69% | 8.91% | -3.27% | -7.50% | -3.41% | 1.69% | -9.29% | -43.66% |
| 2023 | -7.29% | 2.07% | -18.84% | 6.28% | 0.78% | -13.45% | 2.24% | 4.77% | -15.68% | 18.33% | -3.96% | 149.37% | 82.21% |
| 2022 | -27.18% | 6.42% | 4.22% | 8.31% | 0.08% | -1.53% | 7.74% | 25.11% | -8.52% | -9.89% | -2.66% | 7.81% | 0.53% |
| 2021 | -5.34% | -4.78% | 24.19% | 9.37% | -14.19% | -9.34% | 49.97% | 11.08% | 8.40% | -2.32% | 12.69% | 15.86% | 119.35% |
| 2020 | 15.93% | 13.33% | -15.42% | 28.16% | 37.06% | 13.81% | -8.27% | 10.82% | -9.64% | -29.01% | 9.30% | 23.69% | 95.85% |
| 2019 | 11.23% | 2.70% | 12.05% | 9.02% | 17.57% | 8.49% | 8.36% | 15.26% | -19.00% | 2.37% | -17.00% | 9.72% | 67.88% |
| 2018 | 12.88% | -15.76% | -7.10% | 15.28% | 8.43% | -7.78% | -11.45% | 7.48% | 24.68% | -32.08% | 17.49% | -19.59% | -22.45% |
| 2017 | -13.99% | 1.44% | 21.23% | 27.63% | -17.38% | -10.70% | 16.12% | 5.69% | -2.36% | -5.86% | -37.00% | -5.23% | -32.92% |
| 2016 | -26.39% | -18.18% | 11.90% | 15.46% | 0.12% | 16.44% | 17.18% | 8.54% | -23.94% | 5.66% | 23.71% | 1.25% | 16.16% |
| 2015 | -11.49% | 8.74% | -12.06% | -7.23% | 1.27% | 5.49% | -4.91% | 8.29% | -3.32% | 28.70% | 37.28% | -11.51% | 30.59% |
| 2014 | 19.23% | 27.10% | -3.55% | -52.11% | 9.67% | -4.21% | -11.51% | 1.18% | -17.76% | 4.26% | 27.25% | 71.52% | 23.23% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of CYTK is 5, meaning it’s performing worse than 95% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Cytokinetics, Incorporated (CYTK) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Cytokinetics, Incorporated. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Cytokinetics, Incorporated was 97.09%, occurring on Oct 10, 2014. Recovery took 2324 trading sessions.
The current Cytokinetics, Incorporated drawdown is 71.67%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -97.09% | May 6, 2004 | 2627 | Oct 10, 2014 | 2324 | Jan 8, 2024 | 4951 |
| -71.67% | Jan 9, 2024 | 337 | May 13, 2025 | — | — | — |
| -1.52% | May 4, 2004 | 1 | May 4, 2004 | 1 | May 5, 2004 | 2 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Cytokinetics, Incorporated over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Cytokinetics, Incorporated, comparing actual results with analytics estimates. The company met analyst expectations for EPS in the past quarter.
Valuation
The Valuation section provides an overview of how Cytokinetics, Incorporated is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for CYTK compared to other companies in the Biotechnology industry. CYTK currently has a PEG ratio of -0.4. This PEG ratio is negative, which typically signals that the company's earnings are expected to decline. A negative PEG is not considered meaningful for valuation purposes.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for CYTK relative to other companies in the Biotechnology industry. Currently, CYTK has a P/S ratio of 199.7. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for CYTK in comparison with other companies in the Biotechnology industry. Currently, CYTK has a P/B value of 60.3. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |